We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

By Adria Calatayud Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Sanofi SA is to acquire Blueprint Medicines Inc. in a $9.5 billion deal that will give the French pharma ownership of a marketed rare disease immunotherapy heading toward blockbuster status, a ...

Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the ...

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion).

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The collaboration and licence option agreement will focus on identifying and ...

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...